CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

The NDA is supported by data from a clinical trial that compared the absorption and efficacy of the nasal treatment with oral and IV bumetanide in 68 healthy adults.

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

"We are pleased the FDA has accepted our NDA for Bumetanide Nasal Spray," said Benjamin Esque, CEO of Corstasis Therapeutics ...

In our experience, Flonase Allergy Relief Nasal Spray is a highly effective allergy medication that delivers prescription-strength non-drowsy relief all day and night. We found that the nasal ...

The spray, called Spravato, is now the first-ever standalone therapy for treatment-resistant depression, which is when trying at least two standard treatments does little to nothing to improve ...

Share on Pinterest The FDA has approved an esketamine nasal spray for the treatment of depression cases that do not respond to other therapeutic approaches. Image credit: Koldunov/Getty Images.

Ketamine therapy is now a mainstream prescription for treatment-resistant depression. Read more at straitstimes.com.